NOV 06, 2019 10:30 AM PST

Drug discovery and pharmacology of antivirals targeting drug-resistant influenza viruses

Presented at: Influenza 2019
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Assistant Professor, Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona
    Biography
      Dr. Wang received his bachelor degree in chemistry from Wuhan University, China, in 2003. After a one year industry experience in a biotechnology company, he joined Dr. Shaoqin Yao's group at the National University of Singapore in 2004 as a graduate student. His thesis project involves designing and developing chemical probes and inhibitors for matrix metalloproteases. After receiving his master degree in 2006, he moved to the United States and started his PhD study in Dr. William F. DeGrado's laboratory at the University of Pennsylvania. His PhD thesis focuses on rational design of inhibitors targeting drug-resistant influenza A virus M2 proton channels. He is also a major contributor in developing chemical probes to solve the scientific controversy of the drug binding site(s) of M2. After receiving his PhD in chemistry in 2010, he continued as a postdoctoral researcher in the DeGrado lab, first at the University of Pennsylvania and later at the University of California, San Francisco. He started his independent career as an assistant professor at the College of Pharmacy, University of Arizona in 2014. His laboratory mainly focuses on medicinal chemistry and pharmacology of antivirals. Research in the Wang Laboratory is directed towards developing antivirals targeting drug-resistant viruses and emerging viruses, including influenza A and B viruses, enterovirus D68 (EV-D68), EV-A71, coxsackievirus, and polio virus. They are developing inhibitors against multiple viral proteins and use them as chemical probes for target validation. For influenza virus, they have developed inhibitors targeting the M2 proton channel, the viral polymerase PA-PB1 protein-protein interactions, and the hemagglutinin fusion protein. For enteroviruses, they have designed inhibitors targeting the viral capsid VP1 protein, the viral 2A protease, the viral 2C protein, and the viral polymerase. In addition, they are also interested in developing host-targeting antivirals as a means to address drug resistance.

    Abstract

    The efficacy of current influenza antiviral drugs is compromised by emerging drug resistance. To address this unmet medical need, we have made progress in developing novel influenza antivirals by targeting the drug-resistant mutants of M2 and the viral polymerase. In this presentation, I will introduce our work in designing inhibitors targeting the viral M2-S31N mutant proton channel and the viral polymerase PA-PB1 interactions. The designed M2-S31N inhibitors and the PA-PB1 inhibitors have been shown to inhibit drug resistant influenza viruses with potent antiviral efficacy and a high selectivity index. 


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    AUG 27, 2020 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    AUG 27, 2020 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: August 27, 2020 TIME: 7:00am PT Novel anti-viral medications, including biologics and small molecule inhibitors, as well as serologic diagnostic tool sets are in urgent demand to fight...
    JUN 09, 2020 3:00 PM CEST
    C.E. CREDITS
    JUN 09, 2020 3:00 PM CEST
    DATE: June 9, 2020 TIME: 6am PT, 9am ET, 3pm CEST The importance of disposable plastic consumables and their overall impact on the experimental workflow of qPCR has been taken into considera...
    Loading Comments...
    Show Resources
    Attendees
    • See more